Почетна › Карцином на јајниците › Вирџинија › Arlington
Клинички испитувања за Карцином на јајниците во Arlington, VA
46 студии за Карцином на јајниците бараат учесници на локации во и околу Arlington (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
The Vanguard Study: Testing a New Way to Screen for Cancer
Се регрутираДобредојдени се здрави волонтери
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Inova Fair Oaks Hospital, Fairfax · на 11 милји
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Се регрутираФаза 2
- Inova Fairfax Hospital, Falls Church · на 4 милји
- Inova Schar Cancer Institute, Fairfax · на 11 милји
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Се регрутираФаза 1/2
- Research Site, Fairfax · на 11 милји
A Study of PHST001 in Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology - Virginia, Fairfax · на 11 милји
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- NEXT Virginia, Fairfax · на 11 милји
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, Fairfax · на 11 милји
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Се регрутираФаза 2
- Next Virginia /ID# 279684, Fairfax · на 11 милји
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Се регрутираФаза 1
- Site 04, Fairfax · на 11 милји
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Се регрутираФаза 1
- Next Virginia /ID# 278607, Fairfax · на 11 милји
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Се регрутираФаза 1/2
- NEXT Virginia, Fairfax · на 11 милји
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Се регрутираФаза 2
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax · на 11 милји
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Се регрутираФаза 2
- Site 0322 - Inova Schar Cancer Institute, Fairfax · на 11 милји
Study of AVZO-021 in Patients With Advanced Solid Tumors
Се регрутираФаза 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · на 11 милји
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 милји
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Се регрутираФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Се регрутираФаза 3
- Virginia Cancer Specialists (VCS) ( Site 8012), Fairfax · на 11 милји
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Се регрутираФаза 1/2
- NEXT Oncology, Fairfax · на 11 милји
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Се регрутираФаза 3
- Inova Schar Cancer Institute, Fairfax · на 11 милји
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Се регрутираФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 милји
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Се регрутираФаза 1/2
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Next Oncology Virginia, Fairfax · на 11 милји
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Се регрутираФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 милји
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Се регрутираФаза 1
- NEXT Oncology, Fairfax · на 11 милји
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Се регрутираФаза 3
- Virginia Cancer Specialists (VCS) ( Site 8011), Fairfax · на 11 милји
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Се регрутираФаза 1
- Inova Schar Cancer Institute, Falls Church · на 4 милји
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Се регрутираФаза 1
- Normunity Investigational Site, Fairfax · на 11 милји
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Се регрутира
- Inova Fairfax Hospital, Falls Church · на 4 милји
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Inova Fair Oaks Hospital, Fairfax · на 11 милји
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- Clinical Trial Site, Fairfax · на 11 милји
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · на 11 милји
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Се регрутираФаза 1/2
- USOR Virginia Cancer Specialists, Fairfax · на 11 милји
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, Fairfax · на 11 милји
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Се регрутираФаза 2
- 522, Fairfax · на 11 милји
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · на 11 милји
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Се регрутираФаза 1
- NEXT Virginia, Fairfax · на 11 милји
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Се регрутираФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 милји
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- NEXT, Fairfax · на 11 милји
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Се регрутираФаза 3
- Inova Schar Cancer Institute, Fairfax · на 11 милји
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Се регрутираФаза 1
- NEXT Oncology Virginia, Fairfax · на 11 милји
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Се регрутираФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, Fairfax · на 11 милји
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Се регрутираФаза 1
- Dren Investigational Site, Fairfax · на 11 милји
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Се регрутираФаза 1
- Next Oncology, Virginia Cancer Specialists, Fairfax · на 11 милји
Испитувања за Карцином на јајниците во други градови
- Houston, TX89 студии
- New York City, NY69 студии
- Boston, MA61 студија
- Los Angeles, CA50 студии
- Nashville, TN49 студии
- Philadelphia, PA44 студии
- Columbus, OH39 студии
- St. Louis, MO38 студии
- Chicago, IL36 студии
- San Antonio, TX31 студија
- Cleveland, OH30 студии
- Pittsburgh, PA30 студии
Други студии во Arlington
- Рак на бели дробови со не-мали клетки104 студии
- Метастатски карцином53 студии
- Колоректален карцином52 студии
- Рак (сите типови)48 студии
- Рак на дојка47 студии
- Рак на бели дробови41 студија
- Рак на ендометриумот39 студии
- Карцином на панкреасот33 студии
- Сквамозноклеточен карцином на глава и врат26 студии
- Малоклеточен рак на бели дробови23 студии
- Рак на стомакот20 студии
- Трипл негативен рак на дојка20 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.